Table 2 Summary of findings table
From: Hypertonic saline (HS) for acute bronchiolitis: Systematic review and meta-analysis
Assumed risk | Corresponding risk | Relative effect (95 % CI) | No of Participants (studies) | Quality of the evidence (GRADE) | |
|---|---|---|---|---|---|
Outcomes | Normal saline (+/− adjunct treatment) or oxygen therapy plus best supportive care | Hypertonic saline (+/− adjunct treatment) | |||
Hypertonic saline versus normal saline alone (days) | The mean length of hospital stay ranged across control groups from 1.82 to 6.4 days | The mean length of hospital stay ranged across hypertonic saline groups from 1.87 to 4.8 days | 0.58 (95 % CI −0.86 to −0.30) days | 452 (4 inpatient trials) | ⊕ ⊕ ⊕ ⊕ higha |
Hypertonic saline plus B2 agonist vs normal saline plus B2 agonist (days) | The mean length of hospital stay ranged across control groups from 2.66 to 7.4 days | The mean length of hospital stay ranged across hypertonic saline groups from 2.25 to 6 days | 0.18 (95 % CI −0.36 to 0.01 days) | 710 (5 inpatient trials) | ⊕ ⊕ ⊕⊖ moderateb |
Hypertonic saline plus epinepherine vs normal saline plus epinephrine (days) | The mean length of hospital stay ranged across control groups from 1.88 to 5.6 days | The mean length of hospital stay ranged across hypertonic saline groups from 1.4 to 4.9 days | 0.56 (95 % CI −0.86 to −0.27 days) | 470 (5 inpatient trials) | ⊕ ⊕ ⊕ ⊕ highc |
Hypertonic saline alone or plus bronchodilator versus no intervention (days) | The mean length of hospital stay for control groups was 3.7 days | The mean length of hospital stay in the hypertonic saline group was 3.7 days | 0.07 (95 % CI −0.61 to 0.27 days) | 290 (1 inpatient trial) | ⊕ ⊕ ⊕⊖ moderated |